Digestery
Longevity supplements › Rapamycin and Aging › Studies

Animal study

In mice, rapamycin started at 600 days of age extended lifespan

Harrison and colleagues · Nature · 2009

Original title: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Rapamycin extended median and maximal lifespan. Based on age at 90% mortality, lifespan rose 14% in females and 9% in males.

The study at a glance

Type of study
Animal study
Who or what was studied
Male and female mice of mixed genetics at three test sites
What was tested
Rapamycin in food starting at 600 days of age, vs control food
What it measured
The question itself: aging and age-related decline
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Nature, 2009
Source
PubMed record 19587680. This page is based on the abstract only.

How much this study counts

  • –Done in animals. Results in animals often do not carry over to people.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    2

    2 no difference

  3. Trials in people: lab tests or safety

    2

    2 benefit

  4. Population studies

    1

    1 no direction

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

    ↑ This study is the ringed dot

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does rapamycin slow aging in people?”

Not shown in people.

Confidence: very low. Based on 16 on-topic papers.

Read the full answer

Few other papers sit on the same step, so there is little to compare it with.

Other papers on the same step

See all 16 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.